News of Note—Emergent’s new CEO, Valneva’s chikungunya vaccine and more

newspapers
(Pixabay)

Here is some other vaccine news of note for the week:

> Emergent BioSolutions announced that its CEO since 2012, Daniel J. Abdun-Nabi, will retire and be replaced by Robert G. Kramer, Sr., the company’s current president and COO, effective Apr. 1, 2019. Release

> Valneva reported positive phase 1 interim results for its chikungunya vaccine candidate, VLA1553, showing a single vaccination achieved a 100% seroconversion rate at Day 28. The news came as the company announced plans to delist from the Vienna Stock Exchange to focus trading on Euronext Paris. Release | Release

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> Walter Ricciardi, president of Italy’s National Institute of Health, has resigned, accusing the League and Five Star Movement-led government’s antivaccine stance and other “unfounded” health claims. The BMJ article

> The Coalition for Epidemic Preparedness Innovations is making $48 million of funding available to support development of vaccines against Rift Valley fever and chikungunya. Release

Suggested Articles

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.